The Food and Drug Administration recalled more than 3,700 bottles of blood pressure medication that were deemed ineffective.
The FDA issued the Class II recall last week for Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets after lab tests found that the olmesartan component failed quality tests in two lots.
More specifically, the federal agency said dissolution testing revealed the drug doesn’t dissolve appropriately when placed in liquid. This hinders the drug’s efficacy or could lead to an incorrect dose.
People were interested in these podcasts
Olmesartan medoxomil, amlodipine and hydrochlorothiazide help treat high blood pressure, or hypertension.
A Class II recall from the FDA means the medication may cause “temporary or medically reversible adverse health consequences.”
New Jersey-based Macleods Pharmaceuticals issued the recall earlier in October.
The federal recall includes 3,528 30-count bottles from lot 12251163A and 216 90-count bottles from lot 12251163B. Both lots expire on May 31.
Please read our comment policy before commenting.